

Company Heartbeats

Swiss companies - Position yourself with UBS Warrants for upcoming financial results

Company Heartbeats regularly lists companies that will soon present their financial results and for which UBS is offering suitable Warrants. The Warrants are listed on the SIX Structured Products Exchange and tradable on every trading day under normal market conditions. Please consider the disclaimer at the end of this document.

Date	Company	Publication	Share price	Suitable Warrants						
				Type	SIX symbol	Expiry	Leverage	Strike	Ask price	More Warrants
30 Oct 24	Burckardt Comp.	Semi-annual report	CHF 650.00	Call	UNBSDU	21 Mar 25	5.64	700.00	0.19	Calls on Burckardt Comp.
31 Oct 24	Swisscom	Q3 result	CHF 563.00	Call	SBUCMU	21 Mar 25	14.26	580.00	0.15	Calls on Swisscom
				Put	B41S0U	21 Mar 25	13.25	550.00	0.17	Puts on Swisscom
31 Oct 24	Geberit	Q3 result	CHF 523.20	Call	TLUBSU	21 Mar 25	9.78	540.00	0.23	Calls on Geberit
				Put	UMBASU	21 Mar 25	8.02	520.00	0.30	Puts on Geberit
05 Nov 24	Adecco	Q3 result	CHF 28.04	Call	SUGWBU	21 Mar 25	7.65	29.00	0.11	Calls on Adecco
06 Nov 24	Barry Callebaut	Annual report	CHF 1,577.00	Call	ZGUBSU	21 Mar 25	11.43	1,700.00	0.08	Calls on Barry Callebaut
07 Nov 24	AMS	Q3 result	CHF 9.88	Call	BS6U6U	21 Mar 25	3.36	11.00	0.69	Calls on AMS
08 Nov 24	Richemont	Semi-annual report	CHF 129.35	Call	GTCFRU	21 Mar 25	7.81	140.00	0.29	Calls on Richemont
				Put	ULBTSU	21 Mar 25	6.68	120.00	0.31	Puts on Richemont
08 Nov 24	Sandoz	Q3 result	CHF 39.16	Call	SBU35U	21 Mar 25	8.95	41.00	0.35	Calls on Sandoz
12 Nov 24	Alcon	Q3 result	CHF 82.06	Call	UPBSMU	21 Mar 25	10.03	85.00	0.36	Calls on Alcon
				Put	U77S7U	21 Mar 25	8.42	80.00	0.38	Puts on Alcon
14 Nov 24	Swiss Re	Q3 result	CHF 113.60	Call	OSRE9U	21 Mar 25	10.73	120.00	0.24	Calls on Swiss Re
				Put	UB1SVU	21 Mar 25	9.53	110.00	0.31	Puts on Swiss Re
19 Nov 24	Sonova	Semi-annual report	CHF 333.00	Call	XSOOAU	21 Mar 25	8.95	350.00	0.32	Calls on Sonova
				Put	BVZS2U	21 Mar 25	7.06	320.00	0.33	Puts on Sonova
21 Nov 24	BKW	Q3 result	CHF 157.00	Call	BUBSCU	21 Mar 25	9.81	170.00	0.10	Calls on BKW

Source: Refinitiv, UBS.

As of: 29 Oct 24. All prices are indicative.

Company Heartbeats

International companies - Position yourself with UBS Warrants for upcoming financial results

Company Heartbeats regularly lists companies that will soon present their financial results and for which UBS is offering suitable Warrants. The Warrants are listed on the SIX Structured Products Exchange and tradable on every trading day under normal market conditions. Please consider the disclaimer at the end of this document.

Date	Company	Publication	Share price	Suitable Warrants						
				Type	SIX symbol	Expiry	Leverage	Strike	Ask price	More Warrants
30 Oct 24	Meta Platforms	Q3 result	USD 578.16	Call	MET93U	21 Mar 25	6.83	600.00	0.88	Calls on Meta Platforms
30 Oct 24	Microsoft	Q1 result	USD 426.59	Call	2MSF3U	21 Mar 25	9.70	440.00	0.44	Calls on Microsoft
30 Oct 24	Eli Lilly	Q3 result	USD 895.59	Call	00UBSU	21 Mar 25	7.52	950.00	0.56	Calls on Eli Lilly
30 Oct 24	Volkswagen	Q3 result	EUR 91.86	Call	UF5S8U	21 Mar 25	8.82	95.00	0.10	Calls on Volkswagen
31 Oct 24	Amazon	Q3 result	USD 188.39	Call	BKFSPU	21 Mar 25	7.39	195.00	0.26	Calls on Amazon
31 Oct 24	Apple	Annual report	USD 233.40	Call	UOBTSU	21 Mar 25	10.81	245.00	0.19	Calls on Apple
31 Oct 24	Shell	Q3 result	EUR 30.50	Call	UVESRU	21 Mar 25	14.71	32.00	0.17	Calls on Shell
06 Nov 24	Commerzbank	Q3 result	EUR 16.19	Call	ECUBSU	21 Mar 25	7.12	17.00	0.27	Calls on Commerzbank
07 Nov 24	Barrick Gold	Q3 result	USD 19.98	Call	UJFBSU	21 Mar 25	6.96	21.00	0.27	Calls on Barrick Gold
07 Nov 24	Moderna	Q3 result	USD 54.80	Call	BUMS4U	21 Mar 25	3.77	60.00	0.77	Calls on Moderna
12 Nov 24	Bayer	Q3 result	EUR 26.11	Call	2BAYEU	21 Mar 25	7.68	27.00	0.17	Calls on Bayer
14 Nov 24	Alibaba	Semi-annual report	USD 99.93	Call	BSKU5U	21 Mar 25	6.25	105.00	0.40	Calls on Alibaba

Source: Refinitiv, UBS.

As of: 29 Oct 24. All prices are indicative.

Disclaimer

This material has been prepared by UBS AG or one of its affiliates ("UBS"). This material is only intended for the distribution permitted under the applicable law. It has not been prepared for the needs of a specific recipient. It is only published for information purposes and does not constitute an offer or an invitation to purchase or sell securities or associated financial instruments ("Instruments"). UBS accepts no liability (either expressly or tacitly) for the completeness or reliability of the information contained in this document, except for the information on UBS AG and its affiliates. The information should not be regarded by the recipients as a substitute for their own judgment. All the opinions contained herein may change without prior notice and contradict the opinions of other business areas of UBS due to the application of different assumptions and criteria. UBS is not obliged to keep the information up to date. UBS, its executives, employees or clients may have or have had a participation in the Instruments and may conclude transactions with them at any time. UBS may maintain or have maintained a relationship with the entities specified in this information. Neither UBS nor its affiliates, executives or employees are liable for losses resulting from the use of this information.

Structured derivatives do not constitute participation in collective investment schemes. For this reason they do not require approval from the Swiss Financial Market Supervisory Authority (FINMA). As a result, investors are not entitled to the specific investor protection provided by the Swiss Collective Investment Schemes Act (CISA).

Structured products are complex and involve a high risk. The intrinsic value of the investment instruments depends not only on the performance of the underlying asset, but also on the issuer's creditworthiness (credit risk), which can change over the duration of the product. In relation to any securities, currencies, financial instruments or other assets underlying a transaction to which this material relates, the values may fall as well as rise and past performance is not an indication of future performance. Before entering into any transaction, you should consult your own legal, supervisory, tax, financial and accounting advisors as you consider necessary. You should also make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) at your own discretion and based on your consultation with advisors as you consider necessary. Unless expressly agreed otherwise in writing, UBS does not act as financial advisor or fiduciary in any transaction. The terms and conditions of an investment are subject solely to the detailed provisions, including risk considerations, contained in the relevant product documentation. The product documentation, i.e. the prospectus and the Key Information Document (KID), can be obtained from the website keyinvest.ch/en.ubs.com, by entering the relevant security / ISIN. Before you invest in a product, please read the current prospectus and the Key Information Document (KID) carefully and thoroughly. UBS makes no representations or warranties with regard to any information contained herein, which originates from independent sources. This publication may not be copied or reproduced without UBS's prior written permission.

Not for distribution in the United States or to US persons. © UBS 2024. All rights reserved. The key symbol and UBS are among the registered and unregistered trademarks of UBS. UBS prohibits the forwarding of this information without the approval of UBS.

Contact

keyinvest@ubs.com

+41 44 239 76 76*

ubs.com/keyinvest

*Please note that calls to numbers marked with * may be recorded. When you call these numbers, we assume that you consent to this practice.